Many patients who have clogged arteries or survive a heart attack do not consistently take medications prescribed to prevent life-threatening complications, a study confirms.
Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million
Mallinckrodt plc, a leading specialty pharmaceutical company, announced today that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular, for approximately $690 million before tax impacts, including up-front and contingent consideration and the assumption of long-term obligations.
Turing CCO Claims Execs Retaliated After Friend and Co-Founder Resigned Due to Sexual Assault Allegations
Turing Pharmaceuticals, the company that gained notoriety for a 5,000 percent increase on a 65-year-old drug, is once again facing scrutiny – except this time it’s for something much direr. Now the company is under fire for allegedly retaliating against a female employee who filed a sexual assault complaint.
A report shows the kind of damage Zika infections can do to the developing brain – damage that goes well beyond that caused by the devastating birth defect microcephaly.
The vast majority of children and teens should have less than six teaspoons of added sugar in their diet each day, according to the American Heart Association.
The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue.
Florida officials announced the first case of Zika acquired by local mosquitoes in Pinellas County, located some 265 miles (425 km) from Miami, where the first locally transmitted U.S. cases were reported.
A biotech company called Voyager Therapeutics now thinks it can extend the effects of L-Dopa by using a surprising approach: gene therapy.
Two senior lawmakers on the U.S. Senate’s Judiciary Committee pushed for information regarding sharp price increases for EpiPens, drug-filled injectable devices.
International private equity firm Cinven announced a deal to acquire Bioclinica, a global provider of clinical trial services and technology to contract research organizations and pharmaceutical companies, from Water Street Healthcare Partners and JLL Partners.
Pfizer Inc. – beating out numerous other bidders – said it would buy U.S. cancer drug company Medivation Inc. for $14 billion in cash.
New timelines were announced for a U.S. FDA decision on Iglarlixi, the fixed-ratio combination of Adlyxin (lixisenatide) and Lantus, for treating type 2 diabetes.
Verily, Google’s life sciences division, needs more time to complete the construction of its new campus in the Bay Area.
Privately held DS Biopharma is spinning out a new company called Afimmune that is focused solely on fibrotic conditions such as NASH and pulmonary disorders including COPD and IPF.
Donald A. Henderson, who headed the World Health Organization vaccination effort that wiped out smallpox in 1977 and later became a U.S. bioterrorism expert, has died from complications following a hip fracture, officials said.
One of the top U.S. public health officials warned that the mosquito-borne Zika virus could extend its reach across the U.S. Gulf Coast after officials confirmed it as active in the popular tourist destination of Miami Beach.
China’s healthcare system is overly reliant on large over-burdened hospitals, which will struggle to cope with a spike in diseases linked to the fast-aging population, the World Health Organization said.
A Korean investment firm along with three South Korean securities firms has snapped up the North American headquarters of Novo Nordisk for $305 million.
Casebia Therapeutics, a joint venture between Bayer and CRISPR Therapeutics, plans to open laboratory and office space in Cambridge, Mass.
The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences’ heart valves to patients at intermediate risk of complications if they underwent open heart surgery.